Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) butedronate
- Development stage
- Unknown
- Lead developer
- Curium
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium (99mTc) butedronate, commonly referred to as technetium Tc 99m 3,3-diphosphono-1,2-propanedicarboxylic acid (99mTc-DPD), is a diagnostic radiopharmaceutical used as a bone-seeking imaging agent. It consists of the bisphosphonate ligand butedronate labeled with the metastable radionuclide technetium-99m. Upon intravenous administration, the agent rapidly distributes and binds with high affinity to hydroxyapatite crystals in areas of active bone remodeling, making it highly effective for bone scintigraphy to detect skeletal metastases and other bone pathologies. Additionally, technetium (99mTc) butedronate is widely utilized in cardiac scintigraphy for the non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA), where it accumulates in myocardial amyloid deposits via calcium-dependent binding.
- Brand names
- Teceos
- Other names
- 99mTc-DPD99mTc-dicarboxypropane diphosphonatebutedronate technetiumtechnetium (99mTc) DPDtechnetium Tc 99m 3,3-diphosphono-1,2-propanedicarboxylic acidtechnetium Tc 99m butedronatetechnetium Tc 99m DPD
Beyond the preview
Go deeper on technetium (99mTc) butedronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) butedronate.